Transarterial embolization of peripheral high-flow arteriovenous malformation with ethylene vinyl alcohol copolymer (Onyx®): single-center 10-year experience

2018 ◽  
Vol 124 (2) ◽  
pp. 154-162 ◽  
Author(s):  
Francesco Giurazza ◽  
Fabio Corvino ◽  
Gianluca Cangiano ◽  
Errico Cavaglià ◽  
Francesco Amodio ◽  
...  
2016 ◽  
Vol 6 (3) ◽  
pp. 323-327 ◽  
Author(s):  
Olivier Chevallier ◽  
Sophie Gehin ◽  
Alain Foahom-Kamwa ◽  
Pierre Pottecher ◽  
Sylvain Favelier ◽  
...  

2013 ◽  
Vol 36 (5) ◽  
pp. 1288-1295 ◽  
Author(s):  
René Müller-Wille ◽  
Walter A. Wohlgemuth ◽  
Peter Heiss ◽  
Philipp Wiggermann ◽  
Oliver Güntner ◽  
...  

2012 ◽  
Vol 46 (3) ◽  
pp. 251-257 ◽  
Author(s):  
Kamal Massis ◽  
William G. Carson ◽  
Alexandra Rozas ◽  
Vishal Patel ◽  
Bruce Zwiebel

We report our single-center experience in treating 101 type II endoleaks with ethylene-vinyl-alcohol copolymer (EVOH, Onyx). In all, 65 endoleaks were embolized transarterially, and 36 were treated through a translumbar approach. Since the first transarterial embolization, when we began attempts to treat all patients initially via common femoral access, 58 (65.9%) of 88 patients were successfully embolized transarterially. All endoleaks in the translumbar group were successfully treated. At a median follow-up length of 15 weeks, a decrease or stabilization in aneurysm size was observed in 39 (73.6%) of the 53 endoleaks that had adequate follow-up computed tomography imaging. The overall residual endoleak rate was 34.0%. There was no difference in efficacy when comparing transarterial and translumbar approaches. We demonstrate that in most cases, transarterial access of the endoleak nidus is feasible, and controlled embolization is possible using EVOH. Furthermore, EVOH appears effective in long-term stabilization of aneurysm size and in preventing residual endoleaks.


2003 ◽  
Vol 98 (2) ◽  
pp. 366-370 ◽  
Author(s):  
Eric D. Akin ◽  
Eddie Perkins ◽  
Ian B. Ross

Object. There have been significant improvements in neurovascular technology and implants over the past decade. One such material, N-butyl cyanoacrylate (NBCA), is now commercially available for cerebral arteriovenous malformation (AVM) embolization in the US. An ethylene vinyl alcohol copolymer preparation, Onyx, which is currently being evaluated, is approved for use outside North America. Although reports indicate that Onyx may be superior to NBCA from an endovascular perspective, little information exists about its surgical handling characteristics. The purpose of this study was to compare the surgical handling characteristics of Onyx-treated vessels with those of NBCA-embolized vessels in an AVM resection model. Methods. Fourteen pigs (two groups of seven) were anesthetized. A femoral artery was cannulated, followed by selective catheterization of the ascending pharyngeal arteries. Nidal rete mirabile (RM) embolizations were performed using either 6% Onyx or 20% NBCA. After angiographically confirmed obliteration of flow in the right RM, microsurgical resection of this structure was performed. Surgical handling characteristics of the embolized RM were rated on a scale of 1 to 5 and blood loss was recorded. Different surgeons performed the embolizations and resections. The surgeon who performed resections was blinded to the embolization agent used, and the data analysis was also performed in a blinded fashion. The surgical handling scores were superior (p < 0.05) in the Onyx-treated group. Although there was also less blood loss in this group, the difference was not significant. Subjectively, the surgeon who performed the resections believed that Onyx was softer and handled better than NBCA. Conclusions. Onyx, which may offer endovascular advantages, also seems to provide benefits for the surgeon.


Sign in / Sign up

Export Citation Format

Share Document